Background/aims Variceal band ligation (VBL) can reduce the rate of the first variceal by 45-52% compared with b-blockers (BBs). We performed an updated meta-analysis of nine randomized controlled trials published as full papers, comparing VBL with BB for primary prevention.
Introduction
Variceal haemorrhage is the most important clinical complication of portal hypertension. Varices are present in 30% of patients with compensated cirrhosis and in 60% of those with decompensated cirrhosis [1] . Variceal bleeding occurs in up to a third of patients; despite advances in therapy with improved outcomes for patients over the last 20-30 years [2, 3] , the overall mortality ranges between 20 and 50%, depending on the severity of liver disease [1, 4] .
The prevention of variceal haemorrhage is thus an important clinical goal. Propranolol was the first therapeutic agent used for this purpose; this was followed by variceal band ligation (VBL). Two earlier meta-analyses compared b-blockers (BBs) with VBL [5, 6] . In the first meta-analysis, just four trials were studied (two fully published) [5] , whereas the second analysed eight trials (five fully published) [6] . The conclusions from both analyses were similar, with a reduction in the risk of the first variceal bleed in favour of VBL, and no effect on overall or bleeding-related mortality. The second metaanalysis also demonstrated a reduction in the number of adverse events with VBL [6] . There have been four further fully published studies since the last metaanalysis [7] [8] [9] [10] . One study in particular demonstrates results in favour of VBL for both variceal bleeding and mortality resulting in the trial being terminated early [7] . This aroused much controversy, with some clinicians suggesting VBL as first line therapy. Others meanwhile warned against the potential adverse events related to VBL, in particular banding-induced bleeding [11, 12] .
In view of these findings and those of published additional randomized trials, we aim to perform an updated meta-analysis. The outcomes analysed are first variceal bleed, overall mortality, bleed-related mortality and adverse events.
Methods

Data retrieval
The trials were retrieved from 'pubmed ', 'medline' and 'web of knowledge' using the following terms between 1995 and 2006: 'ligation'; 'varices'; 'randomized'; 'b-blockers'. In addition the Cochrane registry was also utilized. Only fully published peer-reviewed studies were considered for inclusion.
Selection criteria
The following criteria were used to select studies: (i) study design: fully published randomized controlled trial (RCT); (ii) patient population: patients with oesophageal varices, secondary to portal hypertension, with no evidence of previous bleeding; (iii) interventions: VBL compared with noncardioselective BB as primary prophylaxis against the first variceal bleed. Where there was more than one publication for the same trial, the results of the most recent paper were used. Decisions to include trials were made by two of the authors (D.T. and P.C.H.) in an unblinded fashion. Reasons for exclusion of trials were identified and agreed upon after discussion.
Outcomes
The following outcomes were assessed when comparing VBL with BB: (i) first variceal bleed; (ii) overall mortality: the number of patients who died during the study period; (iii) bleeding-related mortality: the number of patients who died as a result of variceal bleeding; and (iv) severe adverse events: these were associated with treatment and resulted in withdrawal from the study.
Assessment of trial quality
The five parameters assessed by the two reviewers (D.T. and P.C.H.) were efficacy of generation of randomization list, concealment of treatment allocation, blinded outcome assessment, intention to treat, and completion of follow-up (ideally 90% or more with no significant differences between the two groups) [13, 14] .
Statistical analysis
All outcomes were expressed as relative risk (RR), using 95% confidence interval (CI) estimated by a randomeffects model (Der Simonian and Laird) [18] . If there was a statistically significant difference in the outcome, the numbers needed to treat (NNTs) with 95% CIs were calculated. For a particular outcome, the NNT is the inverse of the absolute difference (risk difference) between the treatment groups.
Heterogeneity was evaluated using the Cochrane w 2 test and was considered significant if the P value was < 0.1.
Publication bias was assessed qualitatively using funnel plots, and quantitatively using the rank correlation test [16, 17] .
Sensitivity analyses were also carried out by using a fixedeffects model (Mantel-Haenszel method) to assess the consistency of results [15] . 
Results
Study selection
A total of 185 references were retrieved, out of which nine eligible fully published trials were selected [7] [8] [9] [10] [19] [20] [21] [22] [23] . The other references were excluded for the following reasons: (i) different patient population or interventions (n = 109); (ii) reference being a review article (n = 38); (iii) reference being not an RCT (n = 13); (iv) reference being an editorial (n = 8); and (v) reference being a letter (n = 8). A total of 734 patients were studied in the nine RCTs (356 in the VBL and 378 in the BB arm). The size of each trial ranged from 31 to 152 patients.
Trial design and quality
All studies are fully published RCTs (Tables 1 and 2) [7-10, [19] [20] [21] [22] [23] . Three of them were multicentre trials involving three [7] , six [21] and 27 [23] centres; although in the trial by Lui and colleagues [21] only two centres had sufficient experience to randomize patients to VBL. Out of 27 centres in one trial, only 10 enrolled more than six patients [23] . Cirrhotic portal hypertension was a mandatory inclusion criterion in all trials except one [20] , whereas hepatic venous pressure gradient Z 12 mmHg was a requirement in two trials [9, 19] . Patients who were selected had larger varices than Grade II [21] or Grade III in two trials [19, 20] , F2 or larger in three trials [9, 10, 22] , of diameter greater than 5 mm in one trial [23] , 3-5 mm varices with red signs or of greater than 5 mm in one trial [7] ; one trial included patients with varices larger than Grade II or F2 [8] . Sample size calculations were performed in five trials [7, 9, [21] [22] [23] . Interim analyses were performed in three trials [7, 21, 23] . Lui and colleagues [21] performed an interim analysis, after 4 years, of a trial that showed increased mortality with nitrates in patients above 50 years of age [24] . They did not find any detrimental effect of nitrates, and trial recruitment was unaffected. Schepke and colleagues [23] planned an interim analysis after 100 patients were recruited, due to uncertainties about the efficacy of VBL. This demonstrated no difference in bleeding rates; hence the investigators concluded that more patients than originally estimated would need to be recruited to show a statistically significant difference. The trial was terminated after consultation with two external sources following recruitment of 152 patients [23] . Jutabha and colleagues [7] planned an interim analysis after 60% of the patients were recruited. The trial was terminated early after this demonstrated a significant benefit of VBL; unlike the trial by Schepke and colleagues [23] no external sources appear to have been consulted. Thuluvath and colleagues [9] prematurely terminated their trial after just 31 patients owing to a low event rate although an interim analysis was not formally performed. The investigators concluded that a far greater number of patients than originally estimated would have been required to show a significant difference.
All trials except one [19] met at least three criteria for trial quality (Table 3 ). This trial did not report on the generation of the randomization list, concealment of treatment allocation and completion of follow-up [19] . Follow-up was not complete in three reported trials [10, 21, 22] , and all patients were included in the final analysis on an intention-to-treat basis. No blinding was performed for outcome assessment in any of the trials. Four trials met the other four criteria, and were considered to be of the highest quality [7, [21] [22] [23] .
Patient characteristics and treatment protocols
Of the 734 patients studied, men constituted over 50% of the total number in all trials; and the mean age was above 50 years in all except two (Table 1) [19, 20] . In two trials, more than 50% patients had alcoholic liver disease [21, 23] . In five trials [7, 9, [19] [20] [21] , there were more patients in Child's class B than in class A or C (range 36-53%), and in four trials [8, 10, 22, 23] there were more patients in Child's class A than in class B or C (range 43-50%). Out of the seven trials [7, 8, [19] [20] [21] [22] [23] in which a breakdown of the size of varices was given, three trials by De et al. [19] (grade IV varices, Z 73% of varices), Jutabha et al. [7] (greater than 5 mm varices, Z 90% of varices) and Schepke et al. [23] (grade III varices, Z 54% of varices) stand out as having more patients with the largest varices (Table 1) . Two trials reported on the North Italian Endoscopic Club (NIEC) score [21, 23, 25] . Full data on the presence of gastric varices were available in seven trials [7, 8, 10, [20] [21] [22] [23] ; these accounted for r 20% of patients in all these trials, except one which accounted for 36% of the patients in the BB arm [22] .
VBL was performed using a single ligator in two trials [10, 20] , multi-bander in six trials [7] [8] [9] 19, 22, 23] , and a combination of single ligator and multibander (from 1995) in one trial ( Table 2 ) [21] . In all trials using the single ligator [10, 20, 21] , an overtube was used wherever necessary, and for every intubation in one trial [10] . The intervals for repeat ligation varied between 1 and 5 weeks, and 2-10 bands were applied at the index session. In two trials, proton pump inhibitors were used routinely after VBL [7, 8] . Variceal eradication was achieved in all patients in three trials [9, 19, 20] after 2.7-3.8 sessions, using an average of nine bands [9, 19] , with recurrent oesophageal varices noted in 20-40%. In the remaining trials, eradication was achieved in 71-93% of patients, with recurrent oesophageal varices in 23-60% [7, 8, 10, [21] [22] [23] . Recurrent varices required fewer banding sessions to eradicate them.
In the BB arms, propranolol (long-acting preparation in two trials [7, 9] , although one of these used the standard preparation after year 3 [7] ) was used in all trials except one [22] where nadolol was used ( Table 2 ). The doses were titrated until a reduction in heart rate of 20-25% of baseline was achieved [7] [8] [9] [10] 19, 20, 22, 23] , or to maintain a systolic blood pressure greater than 100 mmHg and pulse greater than 50 bpm in one trial [21] . In four trials, there was a dose reduction protocol in case of side effects [7, 8, 10, 23] . The mean daily dose of BB was reported by all trials, and varied between 60 and 113.5 mg, with the largest dose being administered in the trial by Lui and colleagues [21] . Compliance was assessed by direct reporting from patients in four trials [8, 9, 20, 21] , by pill count in four trials [7, 19, 22, 23] , and in one trial it was not clear what method was used to assess compliance [10] .
Compliance was reported by all trials and varied between 91 and 100%.
Outcome measures First variceal bleed
First variceal bleed was reported by all trials, and was further defined according to endoscopic or clinical criteria by all but one trial [19] , with one trial using the Baveno III criteria (Table 2 ) [4, 23] . A total of 48 episodes of variceal bleeding occurred with VBL, compared with 82 episodes with BB. The site of variceal bleeding was the oesophagus in all trials except in two, in which 13 episodes of bleeding also occurred from gastric/duodenal varices [10, 22] . In the VBL groups, there were 13 episodes of variceal bleeding before successful eradication of oesophageal varices, including three bleeds induced by VBL in two trials [9, 23] . Four bleeding episodes were reported from recurrent varices after successful eradication in the VBL groups. The pooled RR was significantly in favour of VBL for first variceal bleed (0.63; 95% CI, 0.43-0.92; P = 0.02, Fig. 1) , with the NNT of 13 (95% CI, 7-33). No evidence of heterogeneity (w 2 = 9.18, P = 0.33) or publication bias (rank test, P = 0.35) was seen. Multivariate analysis (Cox proportional hazard regression model) was performed in four trials showing Child's score [22] , female sex or NIEC score greater than 30 [21] , bilirubin or creatinine [23] , and type of therapy (VBL/BB) or grade II/III varices [8] as independent risk factors predicting variceal bleeding.
Mortality
A total of 95 deaths occurred in each of the groups. The pooled RR did not reveal any significant differences between the two groups for overall mortality (1.09; 95% CI, 0.86-1.38; P = 0.47, Fig. 2 ). No evidence of heterogeneity (w 2 = 4.09, P = 0.85) or publication bias (rank test, P = 0.53) was seen. Multivariate analysis performed in three trials showed Child's score [22] , Child's class C or NIEC score greater than 30 [21] , and age or prothrombin index [23] as independent risk factors predicting overall mortality. A total of 15 bleeding-related deaths were seen in the VBL groups, compared with 25 in the BB groups. The pooled RR did not reveal any significant differences between the two groups (0.71; 95% CI, 0.38-1.32; P = 0.28, Fig. 3 ). No evidence of heterogeneity (w 2 = 3.44, P = 0.75) or publication bias (rank test, P = 0.10) was seen.
Adverse events
Adverse events resulting in discontinuation of therapy occurred in seven patients in the VBL groups, and 53 patients in the BB groups. VBL therapy was discontinued in seven patients in total. In five patients, all of whom were from one trial [23] , this was due to bleeding from banding ulcers. In one patient severe bleeding was only controlled with the use of cyanoacrylate. Two patients died, the first from fatal bleeding after VBL-induced ulceration 12 h after VBL, and the second died 3 days after VBL from severe bleeding that was presumably banding-induced, 3 days after VBL, as an endoscopy had Forest plot for overall mortality. CI, confidence interval; RR, relative risk.
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not been performed. The sixth patient bled during a banding session owing to malfunctioning of the device and required sclerotherapy to control bleeding [9] . The seventh patient had perforation of the oesophagus from using the overtube, who recovered with conservative therapy and continued in the banding programme [21] . With BB, the principal events were related to side effects from therapy such as fatigue, shortness of breath, symptomatic hypotension, bradycardia, first-degree heart block and circulation problems [7, 8, 10, [20] [21] [22] [23] . None of these side effects directly resulted in fatalities. Discontinuation of BB therapy resulted in variceal bleeding in 12 patients in four trials [7, 10, 21, 23] , with fatal outcomes in three patients in two trials [10, 23] . The pooled RR was significantly in favour of VBL for adverse events (0.24; 95% CI, 0.12-0.47; P < 0.001, Fig. 4) , with an NNT of 10 (95% CI, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . There was no evidence of heterogeneity (w 2 = 3.65, P = 0.82) or publication bias (rank test, P = 0.10).
Sensitivity analysis
When all the outcomes were assessed using a fixed effects model, there was no change in the statistical significance for first variceal bleed (pooled RR, 0.61; 95% CI, 0.44-0.84; P = 0.003), overall mortality (pooled RR, 1.07; 95% CI, 0.84-1.35; P = 0.58), bleeding-related deaths (pooled RR, 0.63; 95% CI, 0.33-1.20; P = 0.16), or adverse events (pooled RR, 0.20; 95% CI, 0.10-0.39; P < 0.001).
Discussion
The current meta-analysis is the largest till date, comparing VBL and BB in the primary prophylaxis of variceal bleeding, and the first to incorporate only fully published RCTs (n = 9, 1999-2006) resulting in a total of 734 patients [7] [8] [9] [10] [19] [20] [21] [22] [23] . Four of these trials were published in the last year alone [7] [8] [9] [10] . This compares with 283 [5] and 596 patients [6] in previous meta-analyses, both using data from abstracts accounting for 164 and 115 patients, respectively. Clearly, this has limitations such as completeness of data, and the lack of information regarding study protocols. We have shown that VBL is superior to BB therapy for preventing the first variceal haemorrhage and is associated with fewer adverse events that result in treatment discontinuation, with no differences in bleeding-related deaths or overall mortality. No evidence of significant statistical heterogeneity or publication bias was seen.
Some differences existed with regard to the number of patients with alcoholic liver disease, severity of liver disease and size of varices between the trials (Table 1) ; however, there were no significant differences in the two treatment arms within a particular trial. Trials with patients having the largest varices [7, 19, 23] and more advanced liver disease [7, 9, [19] [20] [21] did not appear to have consistently higher bleeding rates. It is important to point out, nevertheless, that within-trials multivariate analysis demonstrated these variables to predict bleeding [8, 22] . The length of follow-up varied between 13 and 35 months. In most trials, the majority of bleeding events occurred within the first year. This is illustrated by the similar bleeding rates in patients in the studies by Sarin et al. [20] (mean follow-up 13-14 months), and by Lay et al. [10] (mean follow-up 35 months). However, all except one study only included patients with cirrhosis [20] . Two trials measured the hepatic venous pressure gradient at baseline [9, 19] , but crucially there was no haemodynamic monitoring during therapy, which would have yielded useful information regarding response rate and allowed for clinical and haemodynamic correlations. It is noteworthy that all the trials were underpowered, despite most being of fair to good quality (Table 3) , and two were terminated early as a result of a low event rate, which would have meant unrealistic large numbers of participants in each arm after revised power calculations [9, 23] . The inclusion criteria were fairly uniform, but in three trials, patients with marked hepatic decompensation were excluded (Table 2) [7, 8, 22] .
The finding of a significant benefit of VBL over BB with an RR reduction of the first variceal bleed of 37% and an NNT of 13 is impressive. In comparison with previous meta-analyses, the tighter CIs in this one resulted in greater statistical significance [5, 6] . Individual results of two trials demonstrated the benefit of VBL, with bleeding rates in the BB arm being high at 27 [20] and 30% [8] , respectively. This can be explained by the rather low dose (60-70 mg) of propranolol used. Haemodynamic monitoring might have been useful to identify the number of nonresponders to BB, as a reduction in the pulse is not particularly reliable in predicting a haemodynamic response [26, 27] . The trial by Jutabha et al. [7] is remarkable for having no bleeding in the VBL arm, despite having a variceal eradication rate of 71%, which is less than that in the other trials. The decision to terminate this trial without independent consultation, on the basis of reduced bleeding and a mortality benefit over BB, is controversial as has been described in a recent correspondence [11] . Even one event in the VBL arm would have resulted in a loss of statistical significance, illustrating the pitfalls of early termination of clinical trials. The low event rate and number of patients in this study has resulted in the trial having a low percentage weight in this meta-analysis ( Fig. 1) .
No difference existed in the overall mortality, which is perhaps not surprising considering the studies were underpowered. Sample sizes of several hundred per treatment arm are needed to be able to show any difference. The differences in bleeding-related mortality are somewhat more interesting. There appears to be a trend towards lower bleeding-related mortality with VBL (15 versus 25 deaths, P = 0.28, Fig. 3 ). The lack of difference might be due to a type II error as a result of small sample sizes. One can expect better results with VBL, given its superiority in preventing the first variceal bleed. No studies were powered to show differences in bleeding-related mortality.
The differences in adverse events resulting in discontinuation of treatment in favour of VBL are striking, with a 76% RR reduction and an NNT of 10. Banding-induced ulceration was noted in 25 patients in total, with bleeding being a result in eight patients (five patients required therapy discontinuation). That banding-induced bleeding was responsible for two fatalities in one trial is noteworthy (although the source of bleeding was not confirmed endoscopically in one patient). The banding protocol was more aggressive than in the other trials with up to 10 bands being placed in one session every week till eradication [23] . The need for such short intervals is questioned by recent evidence showing better eradication of oesophageal varices with two monthly rather than two weekly band ligation [28] ; and one study actually showed a reduced risk of rebleeding from oesophageal varices with intervals Z 3 weeks than with shorter intervals [29] . The role of acid suppression during a banding programme is uncertain, but the two trials in which proton pump inhibitors were used did not have any significant banding-related complications [7, 8] . Perforation of the oesophagus with the use of an overtube (nonfatal) in one trial is an isolated incident [21] , and is likely to be a rare event since overtubes are no longer routinely used. A significant side effect profile was seen with BBs, particularly in one trial that also used the highest dose of propranolol [21] . None of these adverse events, however, were directly fatal, in contrast to VBL. It is noteworthy that 12 patients bled after discontinuation of BB, resulting in three deaths. Clearly, VBL has the potential to cause harm; however, serious events are less likely in the future owing to increasing experience, better training, and also careful patient selection. The importance of the latter is highlighted by a recent study comparing VBL with placebo, in patients intolerant of BB for primary prophylaxis [12] . The study was terminated A meta-analysis of banding versus beta-blockers Tripathi et al. 843
early, owing to VBL-related bleeding in three patients, although there were no statistical differences in bleeding or mortality. The crucial difference between this study and those used for this meta-analysis was that 60% of the patients had small (less than 5 mm) varices. Banding small varices has the potential to cause more damage to the surrounding mucosa, and is not advised. VBL should be restricted to those with moderate to large varices.
The sensitivity analysis using a fixed effects model did not change the results of the outcomes. We are also aware of seven other trials published in abstract form comparing BB and VBL for primary prophylaxis [30] [31] [32] [33] [34] [35] [36] . We chose not to include these studies in the main analysis, owing to a lack of complete data and potential lower quality of the trials. We, however, accept that the exclusion of data from abstracts could be a source of publication bias. We, therefore, performed a separate analysis that included all the abstracts and papers to assess the efficacy of preventing the first variceal bleed and overall mortality. This did not change the overall results; the pooled RRs were 0.56 (95% CI, 0.43-0.74; P < 0.001) and 1.01 (95% CI, 0.82-1.23; P = 0.81) respectively, with no evidence of significant heterogeneity (Table 4 ). Sensitivity analyses performed by separately analysing abstracts and full papers confirmed the results to be robust (Table 4 ). We were unable to assess bleeding-related mortality and adverse events, as these events had not been reported in all abstracts.
In conclusion, we have shown in this meta-analysis that, for primary prophylaxis of patients with moderate to large oesophageal varices, VBL reduced the risk of the first variceal bleed by 37%; there were 76% fewer adverse events resulting in treatment discontinuation, compared with BB. VBL has the potential to result in serious iatrogenic complications. With careful attention to technique and patient selection, however, these events can be minimized.
No effect was seen on overall mortality or bleeding-related mortality with VBL. VBL should be offered to patients with moderate to large oesophageal varices, who are unlikely to comply with drug therapy, to those who are intolerant of or have contraindications to BB, and to patients who bleed on BB therapy. BB therapy still has a role for other groups of patients. Patient preference should also be taken into account whenever possible.
